(Reuters) - Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market.



Latest News

CNBC: Trump reinforces confidence in 'my intelligence people'

CNBC: Netflix tanks after huge subscriber miss

CNBC: Amazon cloud hits snags after Amazon Prime Day downtime

NBC New York: Renovations Keep Long Island Pool Closed

Reuters: Trump on Twitter (July 16): NATO, Russian Meddling

Reuters: Bank of America profit beats on consumer loan growth, lower expenses

WashingtonPost: Trump repudiates U.S. intelligence community by according equal weight to Putin

WashingtonPost: We just watched a U.S. president acting on behalf of a hostile power

WashingtonPost: Trump replaces national pride with personal vanity

FOX: The Latest: Spokesman says officers can conduct pat downs.

CNN: GOP lawmaker: Trump manipulated by Russian intel

CNN: Government shuts down website for doctors searching for treatment guidelines

CNN: Trump clashes with intelligence chief over Russian threat

CBS: Amazon Prime deals: What to avoid, what to buy

CBS: Johnny Depp settles $25M lawsuit against former managers

BBC: Amazon suffers web outages on Prime Day

ABC: Police unaware of man before college student's death

Los Angeles Times: Zsa Zsa Gabor’s former lavish Bel-Air estate returns with a major price markup

Daily Mail: Video: Toddler takes her first steps outside after lung transplant

Daily Mail: Reports: Spurs add F Cunningham

Daily Mail: Venezuela pleads guilty in U.S. to role in PDVSA bribe...

Daily Mail: Report: NFL teams' rev share topped $8B in '17

Daily Mail: Robin Goodfellow's racing tips: Best bets for Tuesday, July 17

17 Related Articles, between 2018-03-22 and 2018-04-16